指南与共识心力衰竭与心肌病血脂与心血管预防

扩张型心肌病患者家属的临床照护:临床共识声明解读

Clinical care of family members of patients with dilated cardiomyopathy.
指南 / 共识 · Eur Heart J · 2025-01-01

该临床共识声明聚焦扩张型心肌病(DCM)先证者检出致病或可能致病变异后对其家属的遗传筛查。声明提出应基于个体与家族层面的遗传和临床信息定制筛查方案,并系统评估家属发生DCM的先验风险。声明还讨论了整合基因型特异性信息、心脏影像和心电图以实现个体化风险预测,并指出早期表型检测与早期治疗干预是研究热点。

要点

  • 推荐对所有一级亲属进行心脏筛查,但家属先验风险因遗传和临床信息而异,需个体化定制筛查方案。
  • 整合基因型特异性信息、心脏影像和心电图有助于个体化风险预测和筛查方案制定。
  • 家属DCM早期表型检测和极轻微表型者的早期治疗干预是活跃研究领域,可能影响未来管理。

核心结论

  • DCM先证者检出致病或可能致病变异后,遗传家属筛查是基因检测的主要应用之一。
  • 家属筛查方案应根据个体和家族层面的遗传与临床信息量身定制,以改善个体化风险预测。

研究设计与样本

  • 本文为欧洲心脏病学会(Eur Heart J)发布的临床共识声明。
  • 声明提供工具以协助家属筛查的风险评估与随访。

主要发现

  • 所有一级亲属均推荐接受心脏筛查,但家属先验风险存在差异。
  • 整合基因型特异性信息、心脏影像和心电图发现可个性化心脏筛查方案。
  • 家属DCM早期表型检测是活跃的研究与创新领域。
  • 关于极轻微表型家属早期治疗干预效用的数据正在积累,可能为未来管理提供参考。

关键数值与推荐

  • 推荐对所有一级亲属进行心脏筛查。
  • 筛查方案应根据遗传和临床信息在个体与家族层面定制。

临床怎么用

  • 对DCM先证者家属,应结合遗传信息和临床评估确定先验风险并制定个体化筛查随访方案。
  • 可将基因型特异性信息、心脏影像和心电图整合用于家属风险预测和筛查方案调整。

局限性

  • 声明指出当前存在知识空白,需改进风险预测、早期疾病检测和治疗。
  • 家属DCM早期表型检测和早期治疗干预的效用仍需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Genetic family screening following the detection of a pathogenic or likely pathogenic variant in a proband with dilated cardiomyopathy (DCM) remains one of the main applications of genetic testing. While cardiac screening is recommended for all first-degree relatives, the a priori risk among family members varies. Consequently, screening regimens should be tailored according to both genetic and clinical information at the individual and familial level. This clinical consensus statement provides tools to help with the risk assessment and follow-up of screening for family members and discusses the utility for integration of genotype-specific information, cardiac imaging, and electrocardiogram findings to personalize cardiac screening regimens, which in conjunction will likely improve individualized risk prediction. Early phenotypic detection of DCM in family members remains an active area of research and innovation. In addition, data are starting to accrue on the utility of early therapeutic intervention in family members with very mild phenotypes that may inform future management in addition to screening. A systematic strategy is proposed to determine the a priori risk of developing DCM for a family member, and the potential of integrating genotype-phenotype knowledge towards family management. Lastly, there is a focus on the current knowledge gaps and ongoing and future opportunities to improve risk prediction, early disease detection, and treatment of family members of patients with DCM.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Verdonschot JAJ, Kaski JP, Asselbergs FW, et al. Clinical care of family members of patients with dilated cardiomyopathy. Eur Heart J. 2025. PMID: 40902100. doi:10.1093/eurheartj/ehaf571

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。